Drug Information

Drug (ID: DG00761) and It's Reported Resistant Information
Name
Ketoprofen
Synonyms
Ketoprofen; 22071-15-4; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; Orudis; m-Benzoylhydratropic acid; Capisten; Ketoprofene; Profenid; Oruvail; Actron; 3-Benzoylhydratropic acid; Alrheumun; Aneol; Epatec; Orudis (TN); Iso-K; Ketoprofeno; RP-19583; Ketoprophene; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-(m-Benzoylphenyl)propionic acid; Racemic ketoprofen; 3-BENZOYL-ALPHA-METHYLBENZENEACETIC ACID; RU 4733; Ketoprofen (Actron); CHEBI:6128; Benzeneacetic acid, 3-benzoyl-.alpha.-methyl-; Alrheumat; CHEMBL571; Propionic acid, 2-(3-benzoylphenyl)-; (S)-Ketoprofen;Dexketoprofen; 19583 RP; L'Acide (benzoyl-3-phenyl)-2-propionique; MLS000079024; Orudis KT; MFCD00055790; NSC-758144; Kefenid; Ketopron; Menamin; Meprofen; Orugesic; Oscorel; SMR000040181; Fastum; Lertus; Toprec; Toprek; Dexal; DSSTox_CID_771; R.P. 19,583; racemic-Ketoprofen; DSSTox_RID_75783; DSSTox_GSID_20771; 1189508-77-7; Ketoprofenum; RP 19583; Ketoprofene [INN-French]; Ketoprofenum [INN-Latin]; Ketoprofeno [INN-Spanish]; Ketoprofen (+-); (+-)-m-Benzoylhydratropic acid; Benzeneacetic acid, 3-benzoyl-alpha-methyl-; SR-01000075949; Ketorin; rac Ketoprofen; CCRIS 4508; Actron ketoprofen; (rs)-ketoprofen; (+-)-3-Benzoyl-alpha-methylbenzeneacetic acid; (+) ketoprofen; NCGC00016757-01; Ketoprofen ,(S); Acide (benzoyl-3-phenyl)-2-propionique [French]; Prestwick_617; EINECS 244-759-8; 2-[3-(benzoyl)phenyl]propanoic acid; CAS-22071-15-4; Ketoprofen-13C-D3; 2-(3-benzoylphenyl)-propionic acid; Hydratropic acid, m-benzoyl-, (+-)-; Acide (benzoyl-3-phenyl)-2-propionique; Spectrum_001309; Opera_ID_509; Prestwick0_000219; Prestwick1_000219; Prestwick2_000219; Prestwick3_000219; Spectrum2_000956; Spectrum3_001479; Spectrum4_000028; Spectrum5_001254; m-benzoyl-hydratropic acid; Epitope ID:131783; K 1751; SCHEMBL2896; Lopac0_000686; Oprea1_117113; BSPBio_000237; BSPBio_003037; Hydratropic acid, m-benzoyl-; KBioGR_000435; KBioSS_001789; MLS000028446; MLS001201752; MLS001306444; MLS002548889; MLS006011967; BIDD:GT0443; DivK1c_000598; SPECTRUM1501215; SPBio_000952; SPBio_002158; Benzeneacetic acid, 3-benzoyl-alpha-methyl-, (+-)-; BPBio1_000261; GTPL4795; IDEA-033; Ketoprofen (JP17/USP/INN); Ketoprofen, >=98% (TLC); DTXSID6020771; DKYWVDODHFEZIM-UHFFFAOYSA-; HMS501N20; KBio1_000598; KBio2_001789; KBio2_004357; KBio2_006925; KBio3_002537; (+/-)-m-Benzoylhydratropic acid; NINDS_000598; HMS1568L19; HMS1921B12; HMS2089B16; HMS2092L19; HMS2095L19; HMS2234H16; HMS3259I05; HMS3262I13; HMS3372M08; HMS3373G09; HMS3649N10; HMS3655C15; HMS3712L19; HMS3884K04; Pharmakon1600-01501215; BCP23428; HY-B0227; 2-(3'-benzoylphenyl)propionic acid; 2-(3-benzoylphenyl) propionic acid; alpha(3-benzoylphenyl)propionic acid; Tox21_110594; Tox21_200847; Tox21_500686; (.+/-.)-m-Benzoylhydratropic acid; 2-(3-benzoylphenyl) propionoic acid; alpha-(m-benzoylphenyl)propionic acid; BDBM50022271; CCG-39685; NSC758144; s1645; STL450995; (R)-(-)-Ketoprofen-[13C,d3]; 2-(3-Benzoylphenyl)propanoic acid #; alpha-(3-benzoylphenyl)propionic acid; AKOS007930512; alpha-(m-benzoylphenyl) propionic acid; Tox21_110594_1; 19583RP; AC-1486; BCP9000810; DB01009; Ketoprofen [USAN:USP:INN:BAN:JAN]; KS-5031; LP00686; MCULE-9740144074; NC00459; NSC 758144; RU-4733; SDCCGSBI-0050664.P004; IDI1_000598; (rs)-2-(3-benzoylphenyl)propanoic acid; NCGC00015578-02; NCGC00015578-03; NCGC00015578-04; NCGC00015578-05; NCGC00015578-07; NCGC00015578-08; NCGC00015578-10; NCGC00015578-12; NCGC00015578-23; NCGC00094043-01; NCGC00094043-02; NCGC00094043-03; NCGC00094043-04; NCGC00258401-01; NCGC00261371-01; BK166172; Ketoprofen 100 microg/mL in Acetonitrile; ((c)I)-Ketoprofen-d4(propionic-d4 acid); 3-Benzoyl-.alpha.-methylbenzeneacetic acid; BCP0726000302; SBI-0050664.P003; (+/-)-2-(3-Benzoylphenyl)propionic acid; L''Acide (benzoyl-3-phenyl)-2-propionique; UNM-0000306100; AB00052249; AM20060549; EU-0100686; FT-0602834; FT-0670646; FT-0670647; K0038; Ketoprofen, meets USP testing specifications; Orudis, Profenid, Dexal, Keduril, Ketofen,; R.P. 19583; SW196784-3; BIM-0050664.0001; C01716; D00132; D78110; Ketoprofen, VETRANAL(TM), analytical standard; AB00052249-17; AB00052249-19; AB00052249-20; AB00052249_21; AB00052249_22; 071K154; A815896; Q409192; Q-201268; SR-01000075949-1; SR-01000075949-6; SR-01000075949-9; (.+/-.)-3-Benzoyl-.alpha.-methylbenzeneacetic acid; Benzeneacetic acid, 3-benzoyl-alpha-methyl-, (+/-); BRD-A97739905-001-05-9; BRD-A97739905-001-15-8; SR-01000075949-18; F2173-0960; Z1695709452; Ketoprofen, British Pharmacopoeia (BP) Reference Standard; Ketoprofen, European Pharmacopoeia (EP) Reference Standard; Ketoprofen, United States Pharmacopeia (USP) Reference Standard; N-FMOC-3-AMINO-4-(4-TERT-BUTOXY-PHENYL)-BUTYRICACID; Ketoprofen, Pharmaceutical Secondary Standard; Certified Reference Material; 154907-35-4
    Click to Show/Hide
Indication
In total 5 Indication(s)
Migraine [ICD-11: 8A80]
Approved
[1]
Musculoskeletal pain [ICD-11: MG30]
Approved
[1]
Osteoarthritis [ICD-11: FA00-FA05]
Approved
[1]
Pain [ICD-11: MG30]
Approved
[1]
Pain [ICD-11: MG30]
Approved
[1]
Structure
Drug Resistance Disease(s)
Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
Ovarian cancer [ICD-11: 2C73]
[1]
Target Prostaglandin G/H synthase 2 (COX-2) PGH2_HUMAN [1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula
C16H14O3
IsoSMILES
CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
InChI
1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
InChIKey
DKYWVDODHFEZIM-UHFFFAOYSA-N
PubChem CID
3825
ChEBI ID
CHEBI:6128
TTD Drug ID
D0W9WF
VARIDT ID
DR00690
INTEDE ID
DR0907
DrugBank ID
DB01009
Type(s) of Resistant Mechanism of This Drug
  IDUE: Irregularity in Drug Uptake and Drug Efflux
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Click to Show/Hide the Resistance Disease of This Class
Ovarian cancer [ICD-11: 2C73]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Irregularity in Drug Uptake and Drug Efflux (IDUE) Click to Show/Hide
Key Molecule: ATP-binding cassette sub-family C2 (ABCC2) [1]
Molecule Alteration Function
Inhibition
 Molecule Info 
Resistant Disease Ovarian cancer [ICD-11: 2C73.0]
 Disease Info 
Experimental Note Revealed Based on the Cell Line Data
In Vitro Model SW48 cells Colon Homo sapiens (Human) CVCL_1724
A2780/RCIS cells Ovary Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration		 Flow cytometric efflux assay
Experiment for
Drug Resistance		 MTT assay
Mechanism Description A new series of quinoline analogs of ketoprofen was designed and synthesized as multidrug resistance protein 2 (MRP2) inhibitors using ketoprofen as the lead compounds.
References
Ref 1 Synthesis and biological evaluation of novel quinoline analogs of ketoprofen as multidrug resistance protein 2 (MRP2) inhibitors .Iran J Basic Med Sci. 2021 Jun;24(6):815-825. doi: 10.22038/ijbms.2021.54554.12265. 10.22038/ijbms.2021.54554.12265

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.